高活性薬理物質受託製造市場-世界の産業規模、シェア、動向、機会、予測、2018～2028年、剤形別、最終用途別、地域別、競合

高活性薬理物質受託製造の世界市場規模は2022年に71億5,000万米ドルとなり、2028年までのCAGRは8.42%で、予測期間中に力強い成長が予測されています。

世界の高活性薬理物質受託製造市場は、製薬およびバイオテクノロジー業界において、複雑で強力な医薬品有効成分（API）の生産において極めて重要な役割を果たす重要なセクターとして浮上しています。高活性薬理物質受託は、極めて高い薬理活性と低用量を特徴とする化合物であり、がん、自己免疫疾患、希少疾患などの疾患に対する標的療法の開発において極めて重要です。製薬会社が精密医療や特殊治療にますます注力するようになるにつれ、高活性薬理物質受託と受託製造サービスの需要が急増し、この市場の成長を牽引しています。

高活性薬理物質受託製造市場の主な促進要因のひとつは、慢性疾患や希少疾患の罹患率が上昇し、新規かつ高活性の薬剤の開発が必要とされていることです。これに加え、いくつかのブロックバスター医薬品の特許切れが重なり、高活性薬理物質受託製造のコスト効率に優れたアウトソーシングの必要性が高まっています。高活性薬理物質受託を専門とする製造受託機関（CMO）は、プロセス開発、スケールアップ、商業規模での生産を含む幅広いサービスを提供し、製薬会社が医薬品開発のスケジュールを短縮し、資本支出を削減することを可能にしています。

さらに、高活性薬理物質受託の取り扱いや製造に関連する厳しい規制要件や安全性への懸念から、製薬会社は最高の安全基準を満たすように設計された封じ込め技術や設備に精通した専門のCMOに依存するようになりました。このため、CMOはアイソレーターやグローブボックスといった最先端のインフラに多額の投資を行い、作業員と環境の両方の保護を確保しています。

世界の高活性薬理物質受託製造市場は激しい競争を特徴としており、多くのCMOがこの分野でリーダーとしての地位を確立しようと競い合っています。この競争が製造技術の革新と進歩を促し、高活性薬理物質受託製造の効率と安全性を向上させています。加えて、この市場は、各社がその能力と地理的範囲を拡大しようとするため、提携、共同研究、買収を示しています。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の高活性薬理物質受託製造市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 剤形別（注射剤、経口固形剤、ローション、その他）
  • 最終用途別（がん、抗糖尿病、自己免疫、その他）
  • 地域別
  • 企業別（2022年）
• 市場マップ
  • 剤形別
  • 最終用途別
  • 地域別

第5章 アジア太平洋の高活性薬理物質受託製造市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製剤別
  • 最終用途別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州の高活性薬理物質受託製造市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 製剤別
  • 最終用途別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米の高活性薬理物質受託製造市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製剤別
  • 最終用途別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米の高活性薬理物質受託製造市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 製剤別
  • 最終用途別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカの高活性薬理物質受託製造市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製剤別
  • 最終用途別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • エジプト

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 製品上市
• 合併と買収

第12章 世界の高活性薬理物質受託製造：SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Catalent, Inc.
• Lonza Group
• Piramal Pharma Solutions
• Pfizer CentreOne
• Gentec Pharmaceutical Group
• AbbVie Contract Manufacturing
• Corden Pharma International
• Curia Global, Inc.
• Merck Group（SigmaAldrich Co., LLC）
• Polpharma Group

第15章 戦略的提言

第16章 調査会社について・免責事項

Global High Potency API (HPAPI) Contract Manufacturing Market has valued at USD USD 7.15 billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 8.42% through 2028. The Global High Potency API (HPAPI) Contract Manufacturing Market has emerged as a vital sector within the pharmaceutical and biotechnology industries, playing a pivotal role in the production of complex and potent active pharmaceutical ingredients (APIs). HPAPIs are compounds characterized by their exceptionally high pharmacological activity and low effective doses, making them crucial in the development of targeted therapies for conditions like cancer, autoimmune diseases, and rare disorders. As pharmaceutical companies increasingly focus on precision medicine and specialized treatments, the demand for HPAPIs and contract manufacturing services has surged, driving the growth of this market.

One of the primary drivers of the HPAPI contract manufacturing market is the rising incidence of chronic and rare diseases, necessitating the development of novel and highly potent drugs. This, coupled with the expiration of patents for several blockbuster drugs, has intensified the need for cost-effective outsourcing of HPAPI production. Contract manufacturing organizations (CMOs) specializing in HPAPIs offer a range of services, including process development, scale-up, and commercial-scale production, enabling pharmaceutical companies to expedite drug development timelines and reduce capital expenditures.

Furthermore, stringent regulatory requirements and safety concerns associated with handling and manufacturing HPAPIs have led pharmaceutical firms to rely on specialized CMOs with expertise in containment technologies and facilities designed to meet the highest safety standards. This has prompted CMOs to invest heavily in state-of-the-art infrastructure, such as isolators and gloveboxes, to ensure the protection of both workers and the environment.

The Global HPAPI Contract Manufacturing Market is characterized by intense competition, with numerous CMOs vying to establish themselves as leaders in the field. This competition has driven innovation and advancements in manufacturing technologies, improving the efficiency and safety of HPAPI production. Additionally, the market has witnessed partnerships, collaborations, and acquisitions as companies seek to expand their capabilities and geographical reach.

Key Market Drivers

Rising Incidence of Chronic and Rare Diseases

The rising incidence of chronic and rare diseases is a significant driving force behind the growth of the Global High Potency API (HPAPI) Contract Manufacturing Market. As the global population ages and lifestyles evolve, the prevalence of chronic diseases like cancer, diabetes, cardiovascular conditions, and autoimmune disorders has been on the rise. Simultaneously, the identification and recognition of rare diseases have improved, shedding light on a category of ailments that affect a smaller but substantial portion of the population.

For pharmaceutical companies, addressing these health challenges necessitates the development of highly specialized medications with precise targeting capabilities and minimal side effects. This is precisely where HPAPIs come into play. Their unique properties, including high pharmacological activity and low effective doses, make them essential for crafting therapies tailored to combat chronic and rare diseases effectively.

Furthermore, as patents for several blockbuster drugs have expired or are nearing expiration, pharmaceutical firms are eager to fill the void with innovative treatments. These next-generation medications often rely on HPAPIs for their potency and precision. In this competitive landscape, pharmaceutical companies are increasingly turning to HPAPI contract manufacturing services to expedite the development and production of these cutting-edge drugs.

The outsourcing of HPAPI production offers multiple advantages for pharmaceutical companies. Firstly, it allows them to harness the expertise and specialized infrastructure of CMOs, reducing the need for massive in-house investments in containment technologies and highly trained personnel. Secondly, it streamlines the drug development process, enabling faster time-to-market and cost-effective solutions. Finally, it ensures compliance with the stringent regulatory requirements governing the manufacturing of high-potency compounds.

As the burden of chronic and rare diseases continues to mount globally, the demand for HPAPI-based medications and the contract manufacturing services supporting their production is expected to remain robust.

Expiry of Patents for Blockbuster Drugs

The expiry of patents for blockbuster drugs has emerged as a potent catalyst driving the growth of the Global High Potency API (HPAPI) Contract Manufacturing Market. Blockbuster drugs, known for generating substantial revenue for pharmaceutical companies, inevitably face patent expiration, opening the door for generic and biosimilar competition. To maintain their competitive edge and revenue streams, pharmaceutical firms are compelled to innovate by developing novel medications, many of which rely on HPAPIs for their therapeutic efficacy.

HPAPIs are essential components of these innovative drugs due to their unparalleled pharmacological potency and precision in targeting specific diseases or conditions. As pharmaceutical companies shift their focus from traditional, widely used medications to specialized therapies with enhanced therapeutic benefits, the demand for HPAPIs has surged.

However, the production of HPAPIs requires specialized facilities, equipment, and expertise, often making in-house manufacturing an expensive and resource-intensive endeavor. This is where HPAPI contract manufacturing services step in as an efficient and cost-effective solution. Contract manufacturing organizations (CMOs) specializing in HPAPIs offer the necessary infrastructure and expertise to expedite the development and production of these cutting-edge drugs.

By outsourcing HPAPI production to specialized CMOs, pharmaceutical companies can minimize their capital expenditures, reduce time-to-market, and harness the advantages of established, state-of-the-art containment technologies. Moreover, CMOs are well-versed in navigating the stringent regulatory landscape governing HPAPI manufacturing, ensuring compliance and safety throughout the production process.

The expiry of patents not only encourages innovation in drug development but also fosters collaboration between pharmaceutical companies and CMOs. Strategic partnerships and agreements between the two entities accelerate the research and production of HPAPI-based medications, ultimately benefiting patients by providing access to advanced therapies..

Technological Advancements

Technological advancements have played a pivotal role in propelling the growth of the Global High Potency API (HPAPI) Contract Manufacturing Market. These advancements have not only improved the efficiency and safety of HPAPI production but have also expanded the possibilities for pharmaceutical companies in the development of novel, highly potent drugs.In the competitive landscape of pharmaceuticals, staying at the forefront of technology is crucial. HPAPIs, known for their exceptional potency, demand precision in handling and manufacturing. As a result, contract manufacturing organizations (CMOs) specializing in HPAPIs have invested significantly in cutting-edge technologies to meet the industry's stringent requirements.

One of the notable advancements is in containment technologies. The development of isolators, gloveboxes, and closed systems has revolutionized the safe handling of HPAPIs. These technologies minimize the risk of exposure to highly potent compounds, protecting both workers and the environment. This enhanced safety has been a critical factor in the growth of the HPAPI contract manufacturing market, as pharmaceutical companies prioritize worker well-being and regulatory compliance.

Furthermore, improvements in process development and manufacturing technologies have streamlined the production of HPAPIs. Advanced techniques enable CMOs to optimize processes, reduce production costs, and minimize waste. These efficiencies benefit pharmaceutical clients by providing cost-effective and scalable solutions, speeding up drug development, and reducing time-to-market. Additionally, the application of cutting-edge analytical tools has enhanced the characterization and quality control of HPAPIs. The ability to precisely analyze and monitor these compounds throughout the production process ensures the highest quality standards, which are paramount in the pharmaceutical industry.

Automation and robotics have also found their place in HPAPI contract manufacturing. These technologies enhance consistency and precision in tasks such as weighing, mixing, and filling, reducing the potential for human error and contamination.

Key Market Challenges

Stringent Regulatory Compliance

Costly Infrastructure and Technology: Building and maintaining facilities that meet the strict safety and containment standards for HPAPI production requires a substantial financial investment. CMOs must invest in specialized equipment, such as isolators and gloveboxes, which come at a high cost. Additionally, they must implement comprehensive quality control systems, which necessitate ongoing investment in technology and personnel training.

Regulatory authorities demand rigorous adherence to Good Manufacturing Practices (GMP) and other stringent guidelines throughout the HPAPI manufacturing process. This means constant monitoring, documentation, and quality assurance measures. Any deviation from these standards can result in regulatory sanctions, delays, or even product recalls, putting immense pressure on CMOs to ensure compliance at all times.

Regulatory standards in the pharmaceutical industry are constantly evolving. Keeping up with these changes and ensuring that manufacturing processes remain compliant with the latest regulations is a perpetual challenge. Failure to adapt to new guidelines can result in costly setbacks and regulatory scrutiny.

The handling of HPAPIs necessitates the implementation of rigorous safety protocols to protect workers and the environment from potential hazards. Maintaining a culture of safety and ensuring that employees are well-trained in handling HPAPIs is an ongoing commitment. This includes investing in specialized training programs and safety equipment.

Comprehensive documentation and reporting are essential in demonstrating compliance with regulatory requirements. Every step of the manufacturing process, from raw material sourcing to final product distribution, must be meticulously documented. The volume and detail of these records can be overwhelming, adding complexity and administrative burden to the operations of CMOs.

Complex Supply Chain Management

The production of HPAPIs often requires sourcing raw materials from different regions around the world. Ensuring a consistent and compliant supply of these materials can be challenging. Variability in quality, regulatory differences, and the logistics of international transportation can all contribute to disruptions in the supply chain.

Maintaining the quality and safety of HPAPIs throughout the supply chain is paramount. This requires rigorous quality control measures, testing, and documentation at every stage, from the sourcing of raw materials to the final product distribution. Any lapse in quality or safety can lead to costly delays or regulatory issues.

Different regions and countries have varying regulatory requirements for pharmaceutical ingredients. Navigating these diverse regulatory landscapes adds complexity to the supply chain, as pharmaceutical companies and contract manufacturing organizations (CMOs) must ensure that their processes and products comply with multiple sets of rules and standards.

International supply chains often involve dealing with suppliers and partners from different cultural backgrounds and languages. Effective communication and understanding across these boundaries are crucial for maintaining smooth operations. Miscommunication can lead to misunderstandings, delays, and mistakes that disrupt the supply chain. Transporting HPAPIs requires specialized handling and packaging to ensure their stability and safety. Delays or mishandling during transportation can jeopardize the quality of the compounds. Additionally, transportation costs can add to the overall expenses of the supply chain.

HPAPIs are valuable and sensitive materials, making them susceptible to theft, counterfeiting, or diversion. Ensuring the security of these compounds as they move through the supply chain is a significant challenge. Robust security measures, including tracking and monitoring, are essential to mitigate these risks.

Key Market Trends

Increasing Focus on Precision Medicine

The increasing focus on precision medicine is a pivotal trend that is significantly boosting the Global High Potency API (HPAPI) Contract Manufacturing Market. Precision medicine, characterized by the customization of healthcare and drug therapies to individual patient profiles, has become a cornerstone of modern medical practice. This approach relies heavily on the development of highly targeted and specialized medications, often formulated with HPAPIs due to their exceptional potency and precision in targeting specific molecular pathways.

Pharmaceutical companies are increasingly dedicating their research and development efforts to precision medicine, aiming to provide tailored treatment options for patients with a wide range of medical conditions. These innovative therapies have demonstrated remarkable potential in improving treatment efficacy while minimizing side effects, making them an attractive choice for healthcare providers and patients alike.

As the demand for precision medicine continues to grow across various therapeutic areas, including oncology, autoimmune diseases, and rare disorders, the role of HPAPIs in drug development has become increasingly prominent. Contract manufacturing organizations (CMOs) specializing in HPAPIs have positioned themselves as indispensable partners in the production of these cutting-edge medications. They offer the necessary expertise, specialized infrastructure, and containment technologies to ensure the safe and efficient manufacturing of HPAPI-based drugs.

The trend toward precision medicine also fuels collaboration between pharmaceutical companies and HPAPI CMOs. These partnerships expedite the development and commercialization of precision therapies, as CMOs contribute their specialized capabilities in HPAPI production. This synergy enables pharmaceutical firms to focus on research and clinical trials while relying on CMOs for cost-effective and compliant HPAPI manufacturing.

Rising Demand for Oncology Therapies

The Global High Potency API (HPAPI) Contract Manufacturing Market is experiencing a significant boost due to the rising demand for oncology therapies. Oncology, the branch of medicine focused on cancer treatment, has witnessed an ever-increasing prevalence of the disease globally. With cancer cases on the rise, the need for potent and targeted oncology therapies has become paramount, and HPAPIs are at the forefront of this battle against cancer.

HPAPIs are instrumental in the development of cutting-edge oncology treatments, offering high pharmacological activity and the ability to precisely target cancer cells while minimizing damage to healthy tissues. These characteristics make HPAPIs a crucial component of many innovative cancer drugs, such as targeted therapies and immunotherapies.

Pharmaceutical companies are continually striving to develop and manufacture more effective and personalized cancer treatments, driving up the demand for HPAPIs. As a result, contract manufacturing organizations (CMOs) that specialize in HPAPIs are experiencing heightened interest and a surge in business from pharmaceutical firms seeking expertise in the production of these high-potency compounds.

CMOs equipped with state-of-the-art facilities and containment technologies are well-positioned to meet the stringent safety and quality standards required for oncology drug production. They offer pharmaceutical companies a cost-effective and efficient solution for producing HPAPI-based oncology therapies, accelerating drug development timelines and improving the chances of bringing innovative treatments to cancer patients.

Furthermore, the rising demand for oncology therapies has led to increased collaboration between pharmaceutical companies and HPAPI CMOs. These collaborations leverage the strengths of both parties, with pharmaceutical firms providing the research and development expertise and CMOs offering specialized HPAPI manufacturing capabilities. This synergy expedites the development and commercialization of oncology drugs, allowing for more rapid access to advanced cancer treatments for patients.

Segmental Insights

Formulation Insights

Based on the Formulation, the Injectables emerged as the dominant segment in the global market for Global High Potency API (HPAPI) Contract Manufacturing Market in 2022 Injectable medications, which include solutions, suspensions, and lyophilized powders, often comprise complex and highly potent compounds. These drugs are commonly used in critical medical situations, such as cancer treatment, autoimmune diseases, and emergency care, where precision and reliability are of utmost importance. As a result, they frequently require HPAPIs to achieve the desired therapeutic effects. The demand for injectables has been on the rise due to the increasing focus on advanced therapies, including biologics, monoclonal antibodies, and cell-based treatments. Many of these therapies rely on HPAPIs to achieve their desired pharmacological activity and specificity, further driving the demand for HPAPI contract manufacturing services.

End Use Insights

Based on the End Use, the Oncology segment emerged as the dominant player in the global market for Global High Potency API (HPAPI) Contract Manufacturing Market in 2022. The global prevalence of cancer continues to increase, making it one of the most prevalent and life-threatening diseases. As a result, the demand for oncology drugs, including targeted therapies and immunotherapies, is continuously growing. Many of these advanced therapies rely on HPAPIs for their high potency and precision in targeting cancer cells. The trend toward precision medicine has gained traction in oncology. Healthcare providers increasingly seek to tailor cancer treatments to the specific genetic or molecular characteristics of individual patients and their tumors. This approach often involves the development of highly specialized medications that require HPAPIs for their precision and efficacy.

Regional Insights

North America emerged as the dominant player in the global High Potency API (HPAPI) Contract Manufacturing Market in 2022, holding the largest market share. North America, particularly the United States, boasts a robust and well-established pharmaceutical industry. The region is home to numerous pharmaceutical companies that are at the forefront of drug development and innovation. This industry strength creates a high demand for HPAPI contract manufacturing services to support the production of specialized and high-potency medications. Oncology remains a significant therapeutic area of focus in North America. The prevalence of cancer and the continuous development of novel oncology drugs have driven the demand for HPAPIs, which are often integral to the formulation of precise and effective cancer treatments. North American pharmaceutical companies are leaders in oncology research and development, further bolstering the demand for HPAPI contract manufacturing.

Key Market Players

Catalent, Inc.

Lonza Group

Piramal Pharma Solutions

Pfizer CentreOne

Gentec Pharmaceutical Group

AbbVie Contract Manufacturing

Corden Pharma International

Curia Global, Inc.

Merck Group (SigmaAldrich Co., LLC)

Polpharma Group

Report Scope:

In this report, the Global High Potency API (HPAPI) Contract Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global High Potency API (HPAPI) Contract Manufacturing Market, By Formulation:

• Injectables
• Oral Solids
• Lotions
• Others

Global High Potency API (HPAPI) Contract Manufacturing Market, By End Use:

• Oncology
• Antidiabetics
• Autoimmune
• Others

Global High Potency API (HPAPI) Contract Manufacturing Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global High Potency API (HPAPI) Contract Manufacturing Market.

Available Customizations:

• Global High Potency API (HPAPI) Contract Manufacturing Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global High Potency API (HPAPI) Contract Manufacturing Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Formulation (Injectables, Oral Solids, Lotions, Others)
  • 4.2.2. By End Use (Oncology, Antidiabetics, Autoimmune, Others)
  • 4.2.3. By Region
  • 4.2.4. By Company (2022)
• 4.3. Market Map
  • 4.3.1. By Formulation
  • 4.3.2. By End Use
  • 4.3.3. By Region

5. Asia Pacific High Potency API (HPAPI) Contract Manufacturing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Formulation
  • 5.2.2. By End Use
  • 5.2.3. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China High Potency API (HPAPI) Contract Manufacturing Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Formulation
      • 5.3.1.2.2. By End Use
  • 5.3.2. India High Potency API (HPAPI) Contract Manufacturing Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Formulation
      • 5.3.2.2.2. By End Use
  • 5.3.3. Australia High Potency API (HPAPI) Contract Manufacturing Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Formulation
      • 5.3.3.2.2. By End Use
  • 5.3.4. Japan High Potency API (HPAPI) Contract Manufacturing Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Formulation
      • 5.3.4.2.2. By End Use
  • 5.3.5. South Korea High Potency API (HPAPI) Contract Manufacturing Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Formulation
      • 5.3.5.2.2. By End Use

6. Europe High Potency API (HPAPI) Contract Manufacturing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Formulation
  • 6.2.2. By End Use
  • 6.2.3. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France High Potency API (HPAPI) Contract Manufacturing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Formulation
      • 6.3.1.2.2. By End Use
  • 6.3.2. Germany High Potency API (HPAPI) Contract Manufacturing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Formulation
      • 6.3.2.2.2. By End Use
  • 6.3.3. Spain High Potency API (HPAPI) Contract Manufacturing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Formulation
      • 6.3.3.2.2. By End Use
  • 6.3.4. Italy High Potency API (HPAPI) Contract Manufacturing Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Formulation
      • 6.3.4.2.2. By End Use
  • 6.3.5. United Kingdom High Potency API (HPAPI) Contract Manufacturing Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Formulation
      • 6.3.5.2.2. By End Use

7. North America High Potency API (HPAPI) Contract Manufacturing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Formulation
  • 7.2.2. By End Use
  • 7.2.3. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States High Potency API (HPAPI) Contract Manufacturing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Formulation
      • 7.3.1.2.2. By End Use
  • 7.3.2. Mexico High Potency API (HPAPI) Contract Manufacturing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Formulation
      • 7.3.2.2.2. By End Use
  • 7.3.3. Canada High Potency API (HPAPI) Contract Manufacturing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Formulation
      • 7.3.3.2.2. By End Use

8. South America High Potency API (HPAPI) Contract Manufacturing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Formulation
  • 8.2.2. By End Use
  • 8.2.3. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil High Potency API (HPAPI) Contract Manufacturing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Formulation
      • 8.3.1.2.2. By End Use
  • 8.3.2. Argentina High Potency API (HPAPI) Contract Manufacturing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Formulation
      • 8.3.2.2.2. By End Use
  • 8.3.3. Colombia High Potency API (HPAPI) Contract Manufacturing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Formulation
      • 8.3.3.2.2. By End Use

9. Middle East and Africa High Potency API (HPAPI) Contract Manufacturing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Formulation
  • 9.2.2. By End Use
  • 9.2.3. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa High Potency API (HPAPI) Contract Manufacturing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Formulation
      • 9.3.1.2.2. By End Use
  • 9.3.2. Saudi Arabia High Potency API (HPAPI) Contract Manufacturing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By End Use
  • 9.3.3. UAE High Potency API (HPAPI) Contract Manufacturing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Formulation
      • 9.3.3.2.2. By End Use
  • 9.3.4. Egypt High Potency API (HPAPI) Contract Manufacturing Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Formulation
      • 9.3.4.2.2. By End Use

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global High Potency API (HPAPI) Contract Manufacturing: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Catalent, Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Lonza Group
• 14.3. Piramal Pharma Solutions
• 14.4. Pfizer CentreOne
• 14.5. Gentec Pharmaceutical Group
• 14.6. AbbVie Contract Manufacturing
• 14.7. Corden Pharma International
• 14.8. Curia Global, Inc.
• 14.9. Merck Group (SigmaAldrich Co., LLC)
• 14.10. Polpharma Group

15. Strategic Recommendations

16. About Us & Disclaimer